{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:30:15Z","timestamp":1793287815971,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V115C-095"],"award-info":[{"award-number":["V115C-095"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114B-015"],"award-info":[{"award-number":["V114B-015"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V115B-008"],"award-info":[{"award-number":["V115B-008"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114C-039"],"award-info":[{"award-number":["V114C-039"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-075 -057 -MY3"],"award-info":[{"award-number":["113-2314-B-075 -057 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["110-2314-B-075-016 MY3"],"award-info":[{"award-number":["110-2314-B-075-016 MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tjog.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:33:44Z","timestamp":1773059624000},"page":"212-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Secondary cytoreductive surgery (S-CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent ovarian cancer: Current evidence and clinical perspectives"],"prefix":"10.1016","volume":"65","author":[{"given":"Che-Wei","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-8541","authenticated-orcid":false,"given":"Peng-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahmana Askandar","family":"Tjokroprawiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2026.01.005_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/JCMA.0000000000001317","article-title":"Programmed death-ligand 1 (PD-L1) upregulation is associated with poor prognosis in patients with epithelial ovarian cancer","volume":"89","author":"Liu","year":"2026","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/JCMA.0000000000001253","article-title":"Is C3c structure useful as biomarkers for epithelial ovarian cancer?","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tjog.2024.11.006","article-title":"Current genetic test for ovarian cancer","volume":"64","author":"Yang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib4","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.tjog.2024.09.002","article-title":"Neoadjuvant chemotherapy is associated with worse prognosis in patients with advanced-stage epithelial ovarian cancer: is it real?","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tjog.2023.11.005","article-title":"Front-line chemoimmunotherapy for treating epithelial ovarian cancer: part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib6","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Gynecologic Oncology Group partners and the European network of gynaecological oncological trial groups. Mirvetuximab soravtansine in FR\u03b1-Positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2026.01.005_bib7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ijgo.15316","article-title":"Recurrent ovarian cancer in Africa: rate and associated factors at a gynecologic oncology treatment center in Ethiopia-A cross-sectional study","volume":"165","author":"Demissie","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2026.01.005_bib8","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2026.01.005_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tjog.2025.12.001","article-title":"Chemoresistance in ovarian cancer (I)","volume":"65","author":"Wang","year":"2026","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.tjog.2024.05.006","article-title":"Evolving treatment paradigms for platinum-resistant ovarian cancer: an update narrative review","volume":"63","author":"Lin","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.tjog.2025.09.019","article-title":"Completeness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tjog.2024.11.003","article-title":"Primary cytoreductive surgery for advanced epithelial ovarian cancer patients is still popular in gynecologic oncologists in Korea and Taiwan, particularly apparent in Taiwan","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.tjog.2024.09.003","article-title":"Primary cytoreductive surgery or interval cytoreductive surgery","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.tjog.2023.09.017","article-title":"Front-line chemo-immunotherapy for treating epithelial ovarian cancer: part I CA125 and anti-CA125","volume":"62","author":"Yang","year":"2023","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/JCMA.0000000000001157","article-title":"Neoadjuvant therapy and locally advanced cancer diseases","volume":"87","author":"Wang","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.tjog.2025.09.018","article-title":"Targeted biomarkers of antibody-drug conjugates (ADCs)","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/JCMA.0000000000001293","article-title":"Optimizing outcomes for the patients with extensive-stage small-cell lung cancer","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/JCMA.0000000000001310","article-title":"A challenge for treating patients with extensive-stage small cell lung cancers, particularly for those with liver metastases","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.tjog.2025.09.003","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (III): understanding of ADC","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/JCMA.0000000000001282","article-title":"Outcomes of everolimus-treated HR+\/HER2- breast cancer","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JCMA.0000000000001283","article-title":"Genomic insights for triple-negative breast cancer patients in Taiwan","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/JCMA.0000000000001255","article-title":"Genomic insights for neuroendocrine prostate cancer","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib23","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/ijgo.70292","article-title":"Targeting the ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) as a potential therapeutic strategy to overcome anti-VEGF resistance in endometrial cancer","volume":"171","author":"Liu","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2026.01.005_bib24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ijgo.16152","article-title":"Identification of vascular hotspots and analysis of micro-vessel flow velocity waveforms in high-grade squamous intraepithelial lesions of the cervix","volume":"170","author":"Wu","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2026.01.005_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.tjog.2024.07.013","article-title":"Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer?","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tjog.2025.10.001","article-title":"The role of secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treating recurrent ovarian cancer","volume":"65","author":"Wang","year":"2026","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/gyno.2000.5738","article-title":"Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent primary serous peritoneal carcinoma: an initial report","volume":"77","author":"Wang","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2026.01.005_bib28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JCMA.0000000000001298","article-title":"Salvage radiotherapy with prostate-specific membrane antigen-directed focal boost: a precision approach for recurrent prostate cancer","volume":"88","author":"Lan","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/JCMA.0000000000001331","article-title":"Management of hormone receptor-positive\/human epidermal growth factor receptor 2-negative breast cancer patients: beyond endocrine therapy","volume":"89","author":"Wang","year":"2026","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/JCMA.0000000000001330","article-title":"Are prioritizing and allocating expensive adjuvant and maintenance therapies beneficial in cancer care?","volume":"89","author":"Wang","year":"2026","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/JCMA.0000000000001308","article-title":"Liver metastases of hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer patients: an ominous sign","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCMA.0000000000001316","article-title":"The impact of brain metastases on outcome in metastatic breast cancer and extensive-stage small cell lung cancer","volume":"89","author":"Wang","year":"2026","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tjog.2024.12.002","article-title":"Is it enough to use cisplatin-paclitaxel-bevacizumab along in the management of stage IVB cervical cancer patients?","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ijgo.15609","article-title":"Bevacizumab is associated with a higher gastrointestinal\/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy","volume":"167","author":"Yang","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2026.01.005_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.111300","article-title":"Efficacy of hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer: a bibliometric analysis and updated meta-analysis","volume":"52","author":"Wei","year":"2026","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.tjog.2026.01.005_bib36","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2026.01.005_bib37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2026.01.005_bib38","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2026.01.005_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102756","article-title":"Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis","volume":"36","author":"Kim","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2026.01.005_bib40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s12957-025-04076-7","article-title":"Efficacy and safety of secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis","volume":"23","author":"Liu","year":"2025","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.tjog.2026.01.005_bib41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cancers17020217","article-title":"The role of cytoreductive surgery in platinum-resistant ovarian cancer (PROC): a systematic review","volume":"17","author":"Sideris","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.tjog.2026.01.005_bib42","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jfma.2024.08.014","article-title":"Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum-resistant recurrent ovarian cancer: a single-center retrospective cohort study","volume":"124","author":"Wu","year":"2025","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2025.07.026","article-title":"The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"200","author":"Bogani","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2026.01.005_bib44","unstructured":"CHIPPI Trial Investigators. Hyperthermic intraperitoneal chemotherapy in primary and interval debulking surgery for ovarian cancer (CHIPPI). ClinicalTrials.gov Identifier: NCT03842982."},{"key":"10.1016\/j.tjog.2026.01.005_bib45","unstructured":"ENGOT-ov52\/OVHIPEC-2 Trial Investigators. HIPEC in newly diagnosed stage III epithelial ovarian cancer. ClinicalTrials.gov Identifier: NCT03772028."},{"key":"10.1016\/j.tjog.2026.01.005_bib46","unstructured":"GOG-3068\/HOTT Trial Investigators. Interval cytoreductive surgery with HIPEC followed by niraparib maintenance in advanced ovarian cancer. ClinicalTrials.gov Identifier: NCT05659381."},{"key":"10.1016\/j.tjog.2026.01.005_bib47","unstructured":"KOV-HIPEC-02 Trial Investigators. HIPEC plus chemotherapy versus chemotherapy alone in platinum-resistant ovarian cancer. ClinicalTrials.gov Identifier: NCT05316181."},{"key":"10.1016\/j.tjog.2026.01.005_bib48","unstructured":"KOV-HIPEC-04 Trial Investigators. HIPEC after neoadjuvant chemotherapy in primary epithelial ovarian cancer. ClinicalTrials.gov Identifier: NCT05827523."},{"key":"10.1016\/j.tjog.2026.01.005_bib49","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2026.37.e75","article-title":"PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but may show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan","volume":"37","author":"Chao","year":"2026","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.tjog.2026.01.005_bib50","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.tjog.2024.09.005","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib51","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tjog.2024.09.006","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (II): anti-HER2\/neu","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib52","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.tjog.2024.06.010","article-title":"Reply to \"glycosylation of FSH and cancer\"","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.tjog.2023.07.034","article-title":"The role of sialylation in gynecologic cancers","volume":"62","author":"Yang","year":"2023","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2026.01.005_bib54","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/JCMA.0000000000000283","article-title":"Immunology and ovarian cancers","volume":"83","author":"Lee","year":"2020","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2026.01.005_bib55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/JCMA.0000000000000252","article-title":"Aberrant sialylation in ovarian cancers","volume":"83","author":"Lee","year":"2020","journal-title":"J Chin Med Assoc"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455926000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455926000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:34:03Z","timestamp":1773059643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455926000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1028455926000227"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2026.01.005","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary cytoreductive surgery (S-CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent ovarian cancer: Current evidence and clinical perspectives","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}